Tag Archive for: cell reprogramming

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development

/in

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized immune response against a patient’s tumors, despite being an off-the-shelf drug Asgard is currently progressing IND-enabling studies of this first-in-class therapy, which reprograms cancer cells in vivo, […]

Read more

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

/in

Study of Asgard’s new cancer immunotherapy modality demonstrates potent anti-tumor effects by turning tumor cells against themselves New data “paves the way for first-in-human trials” of lead program AT-108, which is undergoing CMC development for GMP manufacturing AT-108 is an off-the-shelf gene therapy that induces an immune response tailored against each unique patient’s cancer Lund, […]

Read more

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

/in

Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses Expanding R&D team to further develop AT-108 and broaden in vivo reprogramming […]

Read more